81 related articles for article (PubMed ID: 15482818)
1. Influence of Huntington's disease on the human and mouse proteome.
Zabel C; Klose J
Int Rev Neurobiol; 2004; 61():241-83. PubMed ID: 15482818
[No Abstract] [Full Text] [Related]
2. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy.
Tsang TM; Woodman B; McLoughlin GA; Griffin JL; Tabrizi SJ; Bates GP; Holmes E
J Proteome Res; 2006 Mar; 5(3):483-92. PubMed ID: 16512662
[TBL] [Abstract][Full Text] [Related]
3. Proteomics and alcoholism.
Witzmann FA; Strother WN
Int Rev Neurobiol; 2004; 61():189-214. PubMed ID: 15482816
[No Abstract] [Full Text] [Related]
4. Animal models of Huntington's disease.
Gárdián G
Ideggyogy Sz; 2006 Nov; 59(11-12):396-9. PubMed ID: 17203874
[TBL] [Abstract][Full Text] [Related]
5. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
6. Proteomics--application to the brain.
Marcus K; Schmidt O; Schaefer H; Hamacher M; van Hall A; Meyer HE
Int Rev Neurobiol; 2004; 61():285-311. PubMed ID: 15482819
[No Abstract] [Full Text] [Related]
7. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
Gil JM; Rego AC
Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells.
Dunbar GL; Sandstrom MI; Rossignol J; Lescaudron L
Behav Cogn Neurosci Rev; 2006 Jun; 5(2):63-79. PubMed ID: 16801683
[TBL] [Abstract][Full Text] [Related]
9. Fly models of Huntington's disease.
Marsh JL; Pallos J; Thompson LM
Hum Mol Genet; 2003 Oct; 12 Spec No 2():R187-93. PubMed ID: 12925571
[TBL] [Abstract][Full Text] [Related]
10. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
11. Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin.
Fischer DF; van Dijk R; van Tijn P; Hobo B; Verhage MC; van der Schors RC; Li KW; van Minnen J; Hol EM; van Leeuwen FW
Neurobiol Aging; 2009 Jun; 30(6):847-63. PubMed ID: 18760506
[TBL] [Abstract][Full Text] [Related]
12. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
[TBL] [Abstract][Full Text] [Related]
13. Applications in brain proteomics: 8(th) HUPO Brain Proteome Project Workshop 7 October 2007, Seoul, Korea.
Hamacher M; Stephan C; Hardt T; Eisenacher M; Henkel A; Wiltfang J; Jimenez CR; Park YM; Marcus K; Meyer HE
Proteomics; 2008 May; 8(9):1750-3. PubMed ID: 18384107
[TBL] [Abstract][Full Text] [Related]
14. Quantitative mouse brain proteomics using culture-derived isotope tags as internal standards.
Ishihama Y; Sato T; Tabata T; Miyamoto N; Sagane K; Nagasu T; Oda Y
Nat Biotechnol; 2005 May; 23(5):617-21. PubMed ID: 15834404
[TBL] [Abstract][Full Text] [Related]
15. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain.
Curtis MA; Faull RL; Glass M
J Chem Neuroanat; 2006 Apr; 31(3):210-5. PubMed ID: 16533591
[TBL] [Abstract][Full Text] [Related]
16. Towards a therapy for Huntington's disease (Commentary on Giampà et al.).
Hannan AJ
Eur J Neurosci; 2009 Mar; 29(5):901. PubMed ID: 19291220
[No Abstract] [Full Text] [Related]
17. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
18. Nortriptyline delays disease onset in models of chronic neurodegeneration.
Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
[TBL] [Abstract][Full Text] [Related]
19. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
[TBL] [Abstract][Full Text] [Related]
20. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis.
Henkel C; Roderfeld M; Weiskirchen R; Berres ML; Hillebrandt S; Lammert F; Meyer HE; Stühler K; Graf J; Roeb E
Proteomics; 2006 Dec; 6(24):6538-48. PubMed ID: 17109383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
